15
Oct
2019
Turning Synthetic Biology Into ‘Living Drugs’: Synlogic’s Aoife Brennan on The Long Run
Today’s guest on The Long Run is Aoife Brennan. Aoife (it’s pronounced EE-fuh in her native Ireland) is the CEO of Synlogic Therapeutics. The company, based in Cambridge, Mass., is trying to build on years of work at MIT in synthetic biology. The basic idea is to create what the company calls Synthetic Biotics, or what you can call “Living...Read More 
Share:
10
Oct
2019
UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Oct
2019
12 VCs Who Matter, But You Hardly Ever Read About
This article was first published on November 20, 2017, then revised and updated October 9, 2019 Vinod Khosla, the tech venture capitalist, has said 95 percent of VCs add zero value to a startup other than cash. About four out of every five VCs, he said, actually damage their own investments with bad advice. When asked to apply the Khosla test...Read More
Share:
8
Oct
2019
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Earlier this year, I led a team of 27 biotech professionals to Mt. Kilimanjaro, the highest peak in Africa. Each of us committed to raise $50,000 for cancer research at Fred Hutch. We ended up raising $1.6 million. We had an amazing time together. We all made it to the top. I want to do it again. This time we’re...Read More
Share:
3
Oct
2019
ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Oct
2019
From Farm Field to MIT Lab: Phil Sharp on The Long Run
Today’s guest on The Long Run is Phil Sharp. Phil is one of the world’s most influential biologists and scientific entrepreneurs. Phil won the Nobel Prize in 1993 for his work on RNA splicing. Back in the 1970s in his MIT lab, he looked at the basics of RNA splicing. That paved the way for the discovery of “discontinuous genes.”...Read More
Share:
26
Sep
2019
Big IPO Week On Deck, Amazon & Walmart Health Moves, & Akcea Exec Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
Sep
2019
Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Sep
2019
A Nonprofit That Carried a TB Drug Through the FDA: Bruce Carter on The Long Run
Today’s guest on The Long Run is Bruce Carter. Bruce is the chairman of the board at the New York-based TB Alliance. He’s a senior statesman of the industry, known for his run as CEO of Seattle-based ZymoGenetics, and for serving on a variety of boards. He’s the chairman of the board at Watertown, Mass.-based Enanta Pharmaceuticals, the developer of...Read More
Share:
12
Sep
2019
10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
10
Sep
2019
Hot Job Market Creates Challenges for Companies, Opens Doors for Workers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Sep
2019
Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
4
Sep
2019
Making a Difference for Sickle Cell Disease: Ted Love on The Long Run
Today’s guest on The Long Run is Ted Love. Ted is the CEO of Global Blood Therapeutics, known as GBT for short. The company, based in South San Francisco, is on the cusp of bringing forward the first innovative, disease-modifying medicine for sickle cell disease. GBT has run a pivotal clinical trial in 274 patients, gotten the results published in...Read More
Share:
3
Sep
2019
Dr. Jekyll and Mr. Pharma-Bro: Coping With My Split Personality
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
29
Aug
2019
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Aug
2019
Autoimmunity Research Paves the Way for New Ideas in Halting, Preventing Type 1 Diabetes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
22
Aug
2019
BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Aug
2019
An Unforgettable Experience: The Kilimanjaro Climb to Fight Cancer Yearbook
The Kilimanjaro Climb to Fight Cancer was a marvelous experience. In every way. Weeks later, I’m still absorbing what it means to scientists at Fred Hutch, and to the biotech community. To start, consider the numbers: Our team of 27 climbers raised $1,587,475 for cancer research More than 2,200 donors contributed from around the country 33 sponsors supported the cause...Read More
Share:
20
Aug
2019
Getting in on the Ground Floor of the Biotech Boom: Joel Marcus on The Long Run
Today’s guest on The Long Run is Joel Marcus. Joel is the executive chairman and founder of Alexandria Real Estate Equities. If you have spent five minutes in the biotech industry, you’ve been in one of his buildings. Alexandria is one of just a couple of the big real-estate investment trusts (REITs) that cater to the life sciences industry. ARE...Read More
Share:
20
Aug
2019
As CAR-T Ranks Expand, Industry Scrambles to Solve Long-Standing Manufacturing Challenges
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: